Acoziborole Winthrop, Developed by DNDi and Sanofi, Receives CHMP Positive Opinion as Three-Tablet, Single-Dose Treatment for Most Common Form of Sleeping Sickness
February 28, 2026
February 28, 2026
PARIS, France, Feb. 28 -- Sanofi, a life sciences company, issued the following news release:
* * *
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
* Re . . .
* * *
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
* Re . . .